Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.

Abstract:

:The anti-tumor activity of CpG-containing oligodeoxynucleotides (ODNs) has been well established in numerous animal models and confirmed in a number of early clinical trials. While the use of chemical modifications has effectively reduced the sensitivity of ODNs to nuclease degradation and a number of human trials have yielded promising results, the clinical utility of free CpG ODN still faces several significant challenges that must be addressed to achieve optimal potency and therapeutic activity. These include unfavorable pharmacokinetic/biodistribution characteristics, lack of specificity for target cells and poor intracellular uptake. To overcome these challenges, lipid-based delivery systems have been developed to protect the CpG ODN payload, modify their circulation/distribution characteristics, enhance immune cell targeting and facilitate intracellular uptake. In preclinical cancer models, lipid-mediated delivery has demonstrated the capacity to increase the immunopotency of CpG ODNs and dramatically enhance their anti-tumor efficacy as monotherapies, vaccine adjuvants and combination therapies with monoclonal antibodies or chemotherapy. This review will focus on investigating CpG ODNs as a cancer immunotherapeutic and the promising enhancement in efficacy that can be achieved through the use of lipid nanoparticles as delivery vehicles.

authors

Wilson KD,Tam YK

doi

10.1586/17512433.2.2.181

subject

Has Abstract

pub_date

2009-03-01 00:00:00

pages

181-93

issue

2

eissn

1751-2433

issn

1751-2441

journal_volume

2

pub_type

杂志文章
  • Combating inappropriate use of medicines.

    abstract::Globally, it is possible that less than half of all patients are treated in compliance with guidelines and more than half of all patients fail to take their medicines as prescribed or dispensed. Such inappropriate use is wasteful of resources and causes patient harm in terms of lack of satisfactory outcome, serious ad...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.14

    authors: Holloway KA

    更新日期:2011-05-01 00:00:00

  • Zanamivir for the treatment of avian influenza infections in humans.

    abstract::Zanamivir is currently not recommended by the WHO for the first-line treatment of human influenza A (H5N1) infections. Zanamivir pharmacokinetics and antiviral efficacy were reviewed to assess the basis for this recommendation. Following inhalation of 10 mg zanamivir in healthy humans, the drug is widely distributed t...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.09.60

    authors: Reece PA

    更新日期:2010-01-01 00:00:00

  • Pharmacokinetic drug-drug interactions with methotrexate in oncology.

    abstract::Methotrexate is an antifolate agent used in the treatment of various cancers and some autoimmune diseases. In oncology, methotrexate is frequently administered at a high dose (>1 g/m(2)) and comes with various procedures to reduce the occurrence of toxicity and particularly to ensure optimal renal elimination. Drug-dr...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.57

    authors: Levêque D,Santucci R,Gourieux B,Herbrecht R

    更新日期:2011-11-01 00:00:00

  • Antioxidants in the prevention of myocardial ischemia/reperfusion injury.

    abstract::In acute myocardial ischemia (AMI) the optimal treatment is rapid revascularization by angioplasty or pharmacological thrombolysis. While this is essential to resuscitate the ischemic myocardium, it results in further reperfusion injury and extension of the infarction. The main hypothesis for the mechanism of reperfus...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.09.41

    authors: Qin C,Yap S,Woodman OL

    更新日期:2009-11-01 00:00:00

  • Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.

    abstract:INTRODUCTION:A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of a...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1341308

    authors: Nelson AL

    更新日期:2017-08-01 00:00:00

  • Clinical applications of pharmacogenomics to adverse drug reactions.

    abstract::The problem of adverse drug reactions is a well-documented global public health problem. Recent withdrawals of several widely used prescription medications in the USA and other countries have raised concerns among patients, clinicians, scientists and policy makers. The increasing interest and concern regarding withdra...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.1.2.251

    authors: Issa AM

    更新日期:2008-03-01 00:00:00

  • Efficacy and safety of etoricoxib in the treatment of osteoarthritis.

    abstract::Osteoarthritis is a progressive disease that affects millions of people worldwide, but for which there are no curative options and indeed a limited number of medical treatment options. The American College of Rheumatology recommendations suggest administering either a traditional NSAID or a COX-2-selective inhibitor f...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.1.3.345

    authors: Sebba A

    更新日期:2008-05-01 00:00:00

  • Clinical pharmacokinetic interactions between antiepileptic drugs and hormonal contraceptives.

    abstract::Contraceptive management in women with epilepsy is critical owing to the potential maternal and fetal risks if contraception or seizure management fails. This article briefly describes the pharmacokinetic interactions between antiepileptic drugs (AEDs) and hormonal contraceptives and the rational strategies that may o...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.10.3

    authors: Reddy DS

    更新日期:2010-03-01 00:00:00

  • Statin intolerance: more questions than answers.

    abstract::The dramatic effectiveness of statins in improving the course of atherosclerotic cardiovascular disease tends to overshadow questions of statin intolerance. Thus after more than 25 years of clinical statin use, intolerance remains a poorly understood, frustrating issue for patients and providers. It has been extraordi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2014.857601

    authors: Guyton JR,Campbell KB,Lakey WC

    更新日期:2014-01-01 00:00:00

  • Evidence for a potential protective effect of carnitine-pantothenic acid co-treatment on valproic acid-induced hepatotoxicity.

    abstract::Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world. Hepatotoxicity is a rare but serious side effect resulting from its use, particularly in young patients. This adverse effect does not dis...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.871202

    authors: Felker D,Lynn A,Wang S,Johnson DE

    更新日期:2014-03-01 00:00:00

  • The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice.

    abstract::Calcineurin inhibitors are widely used as maintenance immunosuppressants in solid-organ transplantation to minimize the risk of allograft rejection. Although the use of these agents has transformed the outcomes for patient and graft survival, this has come at a cost, notably the well-known adverse events of nephrotoxi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.49

    authors: Garcia-Saenz-de-Sicilia M,Mukherjee S

    更新日期:2012-09-01 00:00:00

  • Statins and muscle pain.

    abstract::Introduction: Statins remain among the most frequently prescribed drugs and constitute a cornerstone in the prevention of cardiovascular disease. However, muscle symptoms are often reported from patients on statins. Muscle symptoms are frequently reported as adverse events associated with statin therapy.Areas covered:...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1734451

    authors: Pergolizzi JV Jr,Coluzzi F,Colucci RD,Olsson H,LeQuang JA,Al-Saadi J,Magnusson P

    更新日期:2020-03-01 00:00:00

  • Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients.

    abstract:INTRODUCTION:Allogeneic hematopoietic cell transplants (allo-HCT) recipients are at the high-risk of reactivation of cytomegalovirus (CMV), and reactivation is associated with significant morbidity and mortality. Although available anti-CMV therapies may be effective for the prevention of CMV, they are plagued by unacc...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1500897

    authors: Foolad F,Aitken SL,Chemaly RF

    更新日期:2018-10-01 00:00:00

  • Methods for optimizing statistical analyses in pharmacogenomics research.

    abstract::Pharmacogenomics is a rapidly developing sector of human genetics research with arguably the highest potential for immediate benefit. There is a considerable body of evidence demonstrating that variability in drug-treatment response can be explained in part by genetic variation. Subsequently, much research has ensued ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.09.32

    authors: Turner SD,Crawford DC,Ritchie MD

    更新日期:2009-09-01 00:00:00

  • Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future.

    abstract:INTRODUCTION:Large-scale epidemiological studies on Greenlandic, Canadian and Alaskan Eskimos have examined the health benefits of omega-3 fatty acids consumed as part of the diet, and found statistically significant relative reduction in cardiovascular risk in people consuming omega-3 fatty acids. Areas covered: This ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1333902

    authors: Watanabe Y,Tatsuno I

    更新日期:2017-08-01 00:00:00

  • New problems arising from old drugs: second-generation effects of acetaminophen.

    abstract::Acetaminophen (APAP)/paracetamol is one of the most commonly used over-the-counter drugs taken worldwide for treatment of pain and fever. Although considered as safe when taken in recommended doses not higher than 4 g/day, APAP overdose is currently the most important cause of acute liver failure (ALF). ALF may requir...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.944502

    authors: Tiegs G,Karimi K,Brune K,Arck P

    更新日期:2014-09-01 00:00:00

  • Pharmacological resources, diagnostic approach and coordination of care in joint hypermobility-related disorders.

    abstract:INTRODUCTION:Joint hypermobility (JH) is the hallmark of many hereditary soft connective tissue disorders, including Ehlers-Danlos syndromes and related disorders, disorders of the TGFβ-pathway, lateral meningocele syndrome, arterial tortuosity syndrome, and cutis laxa syndromes. Contemporary practice separates individ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1497973

    authors: Baban A,Castori M

    更新日期:2018-07-01 00:00:00

  • Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.

    abstract::Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1665026

    authors: Ahmed SR,Petersen E,Patel R,Migden MR

    更新日期:2019-10-01 00:00:00

  • Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.

    abstract::Inflammation plays a critical role in host defense, maintaining cellular and tissue integrity following chemical, physical and biological insults. Inflammation presents in a variety of acute and chronic disease states and can contribute to disease resolution or progression depending upon the type, magnitude and durati...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.66

    authors: Cressman AM,Petrovic V,Piquette-Miller M

    更新日期:2012-01-01 00:00:00

  • Is single versus combination therapy problematic in the treatment of cutaneous melanoma?

    abstract::Introduction: The development of immunotherapies and targeted therapies has changed the treatment approach in resectable, nonresectable, and metastatic melanoma. Because of their different pharmacological profiles, immunotherapies and/or targeted therapies have been studied in various combinations.Areas covered: We re...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2019.1650641

    authors: Krattinger R,Ramelyte E,Dornbierer J,Dummer R

    更新日期:2020-03-19 00:00:00

  • Immunotherapy for gastric cancers: emerging role and future perspectives.

    abstract:INTRODUCTION:The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical d...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1313113

    authors: Bonotto M,Garattini SK,Basile D,Ongaro E,Fanotto V,Cattaneo M,Cortiula F,Iacono D,Cardellino GG,Pella N,Fasola G,Antonuzzo L,Silvestris N,Aprile G

    更新日期:2017-06-01 00:00:00

  • Use of strong opioids for chronic pain in osteoarthritis: an insight into the Latin American reality.

    abstract:INTRODUCTION:Osteoarthritis is the most common cause of arthritis and one of the main causes of chronic pain. Although opioids are frequently employed for chronic pain treatment, their usage for osteoarthritis pain remains controversial due to the associated adverse effects. Most guidelines reserve their use for refrac...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1381556

    authors: Ruiz Iban MA,Benavides J,Forero JP,Bittelman S,Martinez R,Mite MA,Diaz Heredia J,Ulloa S,Lizárraga Ferrand MM

    更新日期:2018-01-01 00:00:00

  • A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

    abstract::Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1552134

    authors: Esposito A,Viale G,Criscitiello C,Curigliano G

    更新日期:2019-01-01 00:00:00

  • Assessing pharmacological interventions for bone metastases: the need for more patient-centered outcomes.

    abstract::Bone metastases are associated with a broad spectrum of clinical sequelae. Pain, reduced mobility, skeletal complications and treatment-related events reduce quality of life. Numerous randomized controlled trials have evaluated pharmacological interventions to treat bone metastases. The primary outcomes used have evol...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.12.21

    authors: Ford JA,Mowatt G,Jones R

    更新日期:2012-05-01 00:00:00

  • Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.

    abstract:INTRODUCTION:WHO recommends tenofovir, efavirenz, and lamivudine or emtricitabine for first-line antiretroviral therapy (ART) in adults, which replaced more toxic regimens using stavudine, zidovudine or nevirapine. Areas covered: We searched Pubmed to identify observational studies and randomized controlled trials repo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1221760

    authors: Mouton JP,Cohen K,Maartens G

    更新日期:2016-11-01 00:00:00

  • Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.

    abstract:INTRODUCTION:Therapeutic efficiency of NSAID is handicapped by ongoing discussion of cardiovascular (CV) safety. Areas covered: We update meta-analyses on NSAIDs in patients with and without cardiovascular (CV) diseases and analyse the association between NSAIDs and cardiovascular events in patients with inflammation. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1230495

    authors: Zingler G,Hermann B,Fischer T,Herdegen T

    更新日期:2016-11-01 00:00:00

  • Clinical pharmacology of old age.

    abstract::Introduction: With the majority of elderly persons consuming multiple drugs, inappropriate drug use is a major issue in geriatric medicine. Areas covered: We reviewed PubMed, Embase, and Cochrane from inception to 1 May 2019 for potentially inappropriate use of medications, polypharmacy, and age-dependent changes in p...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1632188

    authors: Koren G,Nordon G,Radinsky K,Shalev V

    更新日期:2019-08-01 00:00:00

  • Novel pharmaceuticals in the management of postoperative pain.

    abstract::Novel pharmaceutical advances in postoperative pain management include both non-opioid adjuvants as well as opioid analgesics. Optimizing postoperative analgesics includes improving onset of action, matching duration of analgesia to the setting of use, and minimizing adverse events. To improve on the current standard ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2015.1072465

    authors: Palmer P

    更新日期:2015-01-01 00:00:00

  • Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.

    abstract:INTRODUCTION:Acute bacterial skin and skin structure infections (ABSSSI) are among the most frequent infectious diseases. Recently, several new antibiotics with activity against MRSA have been approved. Tedizolid, a second-generation oxazolidinone approved for ABSSSI offers theoretical advantages over first-generation ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2020.1774362

    authors: Carena AA,Stryjewski ME

    更新日期:2020-06-01 00:00:00

  • Hydrogen sulfide in the endocrine and reproductive systems.

    abstract::Hydrogen sulfide (H(2)S) is now considered a member of a group of signaling molecules termed 'gasotransmitters'. H(2)S has been shown to be generated in the endocrine and reproductive organs and elicits various actions. H(2)S modulates insulin secretion in pancreatic islets. Adipose tissues have the ability to produce...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.10.125

    authors: Zhu XY,Gu H,Ni X

    更新日期:2011-01-01 00:00:00